

## Contents

1.	Р	Purp	oose	. 2
2.	Δ	λрр	lication	. 2
3.			sary and Definitions	
4.			су	
	4.1.		Responsibilities	
	4.2		Dissemination of Related Person Master List	. 4
	4.3		Approval Process	. 4
	4.4	•	Ratification Period	. 6
	4.5		Review of Ongoing Transactions	. 6
	4.6	•	Charitable Contribution	. 7
	4.7		Nepotism Policy	. 7
	4.8	•	Disclosure	. 7
5.	R	Revi	sion history	. 8
6.	R	Revi	ew and Approval Page	. 9

CONFIDETIAL: This document should not be copied, distributed or reproduced	Pag Page <b>1</b> of <b>9</b>	
part, nor passed to any third party		
Print/download inf.: Valid 24		hours when
	printed/downloaded	

GAIN	POLICY			Policy-7
THERAPEUTICS	Title: Related Parties Transactions			Rev.: 1.0
Dpt: GOV	Mandatory for: General	In force date: Dec 05, 2022 12:01:19 (UTC/GMT +01:00 -	ren NA	
		Europe/Brussels)		

### 1. Purpose

Gain Therapeutics, Inc. and its subsidiaries (here in advance, as "the Company") recognizes that Related Person Transactions (as defined below) can present potential or actual conflicts of interest and may raise questions among stockholders as to whether those transactions are consistent with the best interests of the Company and its stockholders. Accordingly, as a general matter, it is the Company's policy to enter into or ratify Related Person Transactions, unless the Board of Directors (the "Board"), acting through the Audit Committee of the Board (the "Committee") or as otherwise described herein, determines that the Related Person Transaction in question is in, or is not inconsistent with, the best interests of the Company and its stockholders, including but not limited to situations where the Company may obtain products or services of a nature, quantity or quality, or on other terms, that are not readily available from alternative sources or when the Company provides products or services to Related Persons (as defined below) on an arm's length basis on terms comparable to those provided to unrelated third parties or on terms comparable to those provided to employees generally. Therefore, the Company has adopted the procedures set forth below for the review, approval or ratification of Related Person Transactions.

This policy is intended to supplement, and not to supersede, other policies that may be applicable to or involve transactions with Related Persons, such as the Code of Business Conduct and Ethics and the Insider Trading Policy.

## 2. Application

This policy is applicable to Gain Therapeutics, Inc. and to its subsidiaries.

### 3. Glossary and Definitions

For the purposes of this policy, a "Related Person Transaction" is a transaction, arrangement or relationship (or any series of similar transactions, arrangements or relationships) in which the Company (including any of its subsidiaries) was, is or will be a participant, and the amount involved exceeds \$100,000, and in which any Related Person had, has or will have a direct or indirect material interest.

For purposes of this Policy, a "Related Person" means:

 any person who is, or at any time since the beginning of the Company's last fiscal year was, a director or executive officer of the Company or a nominee to become a director of the Company;

CONFIDETIAL: This document should not be copied, distributed or reproduced	Pag Page 2 of 9	
part, nor passed to any third party		
Print/download inf.:	hours when	
	printed/downloade	

GAIN	POLI	CY		Policy-7
THERAPEUTICS	Title: Related Parties Transactions			Rev.: 1.0
Dpt: GOV	Mandatory for: General	In force date: Dec 05, 2022 12:01:19 (UTC/GMT +01:00 -	ren. NA	
		Europe/Brussels)		

- 2. any person who is known to be the beneficial owner of more than 5% of any class of the Company's voting securities (a "5% Stockholder");
- 3. any immediate family member of any of the foregoing persons, which means any child, stepchild, parent, stepparent, spouse, sibling, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law of the director, executive officer, nominee or 5% Stockholder, and any person (other than a tenant or employee) sharing the household of such director, executive officer, nominee or 5% Stockholder; and
- 4. any firm, corporation or other entity in which any of the foregoing persons is employed or is a partner or principal or in a similar position or in which such person has a 5% or greater beneficial ownership interest.

## 4. Policy

## 4.1. Responsibilities

<u>Directors, Executive Officers and Nominees</u>. On an annual basis, each director and executive officer shall submit to the Chief Financial Officer the following information: (a) a list of his or her immediate family members (as defined above); (b) for each person listed and, in the case of a director, for the director, the person's employer and job title or brief job description; (c) for each person listed and the director or executive officer, each firm, corporation or other entity in which such person is a partner or principal or in a similar position or in which such person has a 5% or greater beneficial ownership interest; and (d) for each person listed and the director or executive officer, each charitable or non-profit organization for which the person is actively involved in fundraising or otherwise serves as a director, trustee or in a similar capacity.

Any person nominated to stand for election as a director shall submit to the Chief Financial Officer the information described above no later than the date of his or her nomination.

Any person who is appointed as a director or an executive officer shall submit to the Chief Financial Officer the information described above prior to such person's appointment as a director or executive officer, except in the case of an executive officer where due to the circumstances it is not practicable to submit the information in advance, in which case the information shall be submitted as soon as reasonably practicable following the appointment.

Directors and executive officers are expected to notify the Chief Financial Officer of any updates to the list of Related Persons, their employment and relationships with charitable organizations. Generally this would include notification of the marriage of the director or executive officer, or the marriage of his or her sibling or child.

The Legal Counselor, by examining SEC filings and through the use of Internet search engines and a review of applicable websites, shall, if necessary, expand the lists provided by directors, executive

CONFIDETIAL: This document should not be copied, distributed or reproduced	Pag Page <b>3</b> of <b>9</b>	
part, nor passed to any third party		
Print/download inf.:	hours when	
	printed,	

GAIN	POLI	CY		Policy-7
THERAPEUTICS	Title: Related Parties Transactions			Rev.: 1.0
Dpt: GOV	Mandatory for: General	In force date: Dec 05, 2022 12:01:19 (UTC/GMT +01:00 -	ren NA	
		Europe/Brussels)	.,,	

officers and nominees by adding parent companies, subsidiaries and sibling companies, as applicable, of the firms, companies or entities set forth on the lists.

The Legal Counselor, on an annual basis, by examining SEC filings and through the use of Internet search engines and a review of applicable websites, shall, if necessary, update the lists provided by directors, executive officers and nominees to reflect changes in family, changes in employment, and the addition of new parent companies, subsidiaries and sibling companies, as well as any updated information provided by the directors, executive officers and nominees. Copies of such updated lists will be provided to the relevant directors and executive officers.

<u>Five Percent Owners</u>. At the time the Company becomes aware of a person's status as a beneficial owner of more than 5% of any class of the Company's voting securities, the Legal Counselor, by examining SEC filings and through the use of Internet search engines and a review of applicable websites, shall create a list, to the extent the information is readily available, of (a) if the person is an individual, the same information as is requested of directors and executive officers under this policy and (b) if the person is a firm, corporation or other entity, a list of principals or executive officers of the firm, corporation or entity, and shall update the list on an annual basis.

#### 4.2. Dissemination of Related Person Master List

The Legal Counselor shall compile the information collected pursuant to the procedures described in Section C above and create a master list of Related Persons. The Legal Counselor shall distribute the master list (and the quarterly updates thereof) to (a) business unit and function/department leaders responsible for purchasing goods or services for the Company or selling the Company's goods or services and (b) the Chief Financial Officer, the director of accounts payable and the director of accounts receivable. The recipients of the master list shall utilize the information contained therein, in connection with their respective business units, departments and areas of responsibility, to effectuate this policy.

## 4.3. Approval Process

Related Person Transactions that are identified as such prior to the consummation thereof or amendment thereto shall be consummated or amended only if the following steps are taken:

1. Prior to entering into the Related Person Transaction (a) the Related Person, (b) the director, executive officer, nominee or beneficial owner who is an immediate family member of the Related Person, or (c) the business unit or function/department leader responsible for the potential Related Person Transaction shall provide notice to the Legal Counselor of the facts and circumstances of the proposed Related Person Transaction, including: (i) the Related Person's relationship to the Company and interest in the transaction; (ii) the material facts

CONFIDETIAL: This document should not be copied, distributed or reproduced	Pag Page <b>4</b> of <b>9</b>	
part, nor passed to any third party		
Print/download inf.:	hours when	
	printed,	downloaded/

GAIN	POLICY			
THERAPEUTICS	Title: Related Parties Transactions		Rev.: 1.0	
Dpt: GOV	Mandatory for: General	In force date: Dec 05, 2022	ren	
		12:01:19 (UTC/GMT +01:00 -	NA	
		Europe/Brussels)		

of the proposed Related Person Transaction, including the proposed aggregate value of such transaction or, in the case of indebtedness, the amount of principal that would be involved; (iii) the benefits to the Company of the proposed Related Person Transaction; (iv) if applicable, the availability of other sources of comparable products or services; and (v) an assessment of whether the proposed Related Person Transaction is on terms that are comparable to the terms available to an unrelated third party or to employees generally. In the event the notice is provided to the Legal Counselor by someone other than the business unit or function/department leader responsible for the potential Related Person Transaction, a member of the Legal Counselor shall meet with the relevant business unit or function/department leader to confirm and supplement the information provided in the original notice. The Legal Counselor will assess whether the proposed transaction is a Related Person Transaction for purposes of this policy.

- 2. If the Legal Counselor determines that the proposed transaction is a Related Person Transaction, the proposed Related Person Transaction shall be submitted to the Committee for consideration at the next Committee meeting or, in those instances in which the Legal Counselor, in consultation with the Chief Executive Officer or the Chief Financial Officer, determines that it is not practicable or desirable for the Company to wait until the next Committee meeting, to the Chair of the Committee (who will possess delegated authority to act between Committee meetings).
- 3. The Committee, or where submitted to the Chair, the Chair, shall consider all of the relevant facts and circumstances available to the Committee or the Chair, including (if applicable) but not limited to: the benefits to the Company; the impact on a director's independence in the event the Related Person is a director, an immediate family member of a director or an entity in which a director is a partner, shareholder or executive officer; the availability of other sources for comparable products or services; the terms of the transaction; and the terms available to unrelated third parties or to employees generally. No member of the Committee shall participate in any review, consideration or approval of any Related Person Transaction with respect to which such member or any of his or her immediate family members is the Related Person. The Committee (or the Chair) shall approve only those Related Person Transactions that are in, or are not inconsistent with, the best interests of the Company and its stockholders, as the Committee (or the Chair) determines in good faith. The Committee or Chair, as applicable, shall convey the decision to the Legal Counselor, which shall convey the decision to the appropriate persons within the Company.
- 4. The Chair of the Committee shall report to the Committee at the next Committee meeting any approval under this policy pursuant to delegated authority.

CONFIDETIAL: This document should not be copied, distributed or reproduced	Pag Page <b>5</b> of <b>9</b>	
part, nor passed to any third party		
Print/download inf.:	hours when	
	printed,	

GAIN	POLICY			Policy-7
THERAPEUTICS	Title: Related Parties Transactions			Rev.: 1.0
Dpt: GOV	Mandatory for: General	In force date: Dec 05, 2022 12:01:19 (UTC/GMT +01:00 -	ren. NA	
		Europe/Brussels)		

#### 4.4. Ratification Period

The Chief Financial Officer shall produce annual reports of any amounts paid or payable to, or received or receivable from, any Related Person, and those reports shall be provided to the Legal Counselor to determine if there are any Related Person Transactions that were not previously approved or previously ratified under this policy.

In the event the Company's Chief Executive Officer, Chief Financial Officer or Legal Counselor becomes aware, as a result of the accounts payable/accounts receivable reports described above or otherwise, of a Related Person Transaction that has not been previously approved or previously ratified under this policy:

- 1. If the transaction is pending or ongoing, it will be submitted to the Committee or Chair of the Committee promptly, and the Committee or Chair shall consider all of the relevant facts and circumstances available to the Committee or the Chair, including (if applicable) but not limited to: the benefits to the Company; the impact on a director's independence in the event the Related Person is a director, an immediate family member of a director or an entity in which a director is a partner, shareholder or executive officer; the availability of other sources for comparable products or services; the terms of the transaction; and the terms available to unrelated third parties or to employees generally. Based on the conclusions reached, the Committee or the Chair shall evaluate all options, including but not limited to ratification, amendment or termination of the Related Person Transaction; and
- If the transaction is completed, the Committee or Chair of the Committee shall evaluate the transaction, taking into account the same factors described above, to determine if rescission of the transaction or other action is appropriate, and shall request that the Legal Counselor evaluate the Company's controls and procedures to ascertain the reason the transaction was not submitted to the Committee or Chair for prior approval and whether any changes to these procedures are recommended.

## 4.5. Review of Ongoing Transactions

If a Related Party Transaction will be ongoing, the Committee may establish guidelines for management to follow in its ongoing dealings with the Related Person and with regard to the Related Party Transaction. Thereafter, on at least an annual basis, the Committee shall review and assess ongoing relationships with the Related Person to see that they are in compliance with the Committee's guidelines and that such transaction(s) remain(s) appropriate Based on all relevant facts and circumstances, taking into consideration the Company's contractual obligations, the

CONFIDETIAL: This document should not be copied, distributed or reproduced	Pag Page <b>6</b> of <b>9</b>	
part, nor passed to any third party		
Print/download inf.:	4 hours when	
printed,		/downloaded

GAIN	POLICY			Policy-7
THERAPEUTICS	Title: Related Parties Transactions			Rev.: 1.0
Dpt: GOV	Mandatory for: General	In force date: Dec 05, 2022 12:01:19 (UTC/GMT +01:00 -	ren. NA	
		Europe/Brussels)		

Committee shall determine if it is in the best interests of the Company and its stockholders to continue, modify or terminate the Related Person Transaction.

#### 4.6. Charitable Contribution

Proposed charitable contributions, or pledges of charitable contributions, by the Company to a charitable or non-profit organization identified on the roster of Related Persons shall be subject to prior review and approval by the Committee at the next Committee meeting or, in those instances in which the Legal Counselor, in consultation with the Chief Executive Officer or the Chief Financial Officer, determines that it is not practicable or desirable for the Company to wait until the next Committee meeting, by the Chair of the Committee. In addition, each "named executive officer" (as defined by SEC rules) shall report to the Legal Counselor, and the Legal Counselor shall consolidate the information and report to the Committee, on an annual basis, charitable contributions in excess of \$100,000, in the aggregate, by the Company's named executive officers and their spouses to charitable or non-profit organizations identified on the roster of Related Persons.

## 4.7. Nepotism Policy

No immediate family member of a director or executive officer shall be hired as an employee of the Company unless the employment arrangement is approved by the Committee at the next Committee meeting or, in those instances in which the Legal Counselor, in consultation with the Chief Executive Officer or the Chief Financial Officer, determines that it is not practicable or desirable for the Company to wait until the next Committee meeting, by the Chair of the Committee. In the event a person becomes a director or executive officer of the Company and an immediate family member of such person is already an employee of the Company, no material change in the terms of employment, including compensation, may be made without the prior approval of the Committee (except, if the immediate family member is himself or herself an executive officer of the Company, any proposed change in the terms of employment shall be reviewed and approved in the same manner as other executive officer compensatory arrangements).

#### 4.8. Disclosure

All Related Person Transactions that are required to be disclosed in the Company's filings with the Securities and Exchange Commission, as required by the Securities Act of 1933 and the Securities Exchange Act of 1934 and related rules and regulations, shall be so disclosed in accordance with such laws, rules and regulations.

The material features of this policy shall be disclosed in the Company's annual report on Form 10-K or in the Company's proxy statement, as required by applicable laws, rules and regulations.

CONFIDETIAL: This document should not be copied, distributed or reproduced	Pag Page <b>7</b> of <b>9</b>	
part, nor passed to any third party		
Print/download inf.:	.: Valid 24 h	
	printed/downloaded	

GAIN	POLICY		Policy-7	
THERAPEUTICS	Title: Related Parties Transactions		Rev.: 1.0	
Dpt: GOV	Mandatory for: General	In force date: Dec 05, 2022 12:01:19 (UTC/GMT +01:00 -	ren NA	
		Europe/Brussels)	14/	

## 5. Revision history

Date	Change description	Rev. numb.
03 Mar 2021	Policy Approved by the Board of Director	NA
Dec 05, 2022	Formatting change and uploading to the electronic Quality	1.0
12:01:19	Management System	
(UTC/GMT		
+01:00 -		
Europe/Brussels)		

CONFIDETIAL: This document should not be copied, distributed or reproduced	Pag Page 8 of 9	
part, nor passed to any third party		
Print/download inf.: Valid 24		hours when
printed/downloade		downloaded/

GAIN	POLICY		Policy-7	
THERAPEUTICS	Title: Related Parties Transactions		Rev.: 1.0	
Dpt: GOV	Mandatory for: General	In force date: Dec 05, 2022 12:01:19 (UTC/GMT +01:00 -	ren NA	
		Europe/Brussels)		

# 6. Review and Approval Page

	Name	Title	Date
Prepared by	Salvatore Calabrese	Chief Financial Officer	Nov 14, 2022 14:21:46 (UTC/GMT +01:00 - Europe/Brussels)
	Terenzio Ignoni	SVP Technical Operations	Nov 14, 2022 13:55:45 (UTC/GMT +01:00 - Europe/Brussels)
Reviewed by	Terenzio Ignoni	SVP Technical Operations	Nov 14, 2022 16:10:01 (UTC/GMT +01:00 - Europe/Brussels)
approved by	Matthias Alder	Chief Executive Officer	Nov 30, 2022 23:10:56 (UTC/GMT +01:00 - Europe/Brussels)

**NOTE:** Signature manifestation reported in this page does not necessary report all the authors, reviewers and approvers of this document.

CONFIDETIAL: This document should not be copied, distributed or reproduced	Pag Page <b>9</b> of <b>9</b>	
part, nor passed to any third party		
/download inf.: Valid 24		hours when
	printed/downloaded	